Kevin Outterson

Kevin Outterson, J.D., LL.M., is Professor of Law and Austin B. Fletcher Professor of Law at Boston University, where he leads the Social Innovation on Drug Resistance program, and is Visiting Professor in the Faculty of Medicine at Imperial College, London. He is also the founding Executive Director and Principal Investigator of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership funded by the U.S., U.K., and German governments, Wellcome and the Bill & Melinda Gates Foundation. Its mission is to accelerate a diverse portfolio of innovative antibacterial products toward clinical development and regulatory approval. The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibacterial therapeutics, diagnostics, and prevention. CARB-X is the only global partnership that includes prevention, diagnosis, and treatment of life-threatening bacterial infections. CARB-X has been awarded over $800 million in grants with Professor Outterson as Principal Investigator.

Professor Outterson’s primary areas of expertise are the law and economics of antimicrobial resistance, particularly push and pull incentives for antimicrobials. Professor Outterson has participated in many major reports and initiatives on antibacterial research and development. He served on the Advisory Panel for the Longitude Prize that offers an award for inventors creating affordable and rapid diagnostics to help clinicians identify effective antibiotics to treat drug-resistant bacteria. Professor Outterson received the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work.

Professor Outterson publishes in legal and peer-reviewed medical and health policy journals, including Yale Journal of Health Policy, Law and Ethics; Cardozo Law Review; University of Pittsburgh Law Review; Kansas Law Review; American Journal of Law & Medicine; New England Journal of Medicine; Health Affairs; The Lancet Infectious Diseases; Environmental Philosophy; The Medical Journal of Australia; Journal of Generic Medicines; Clinical Infectious Diseases; and Journal of Law, Medicine & Ethics.